C4 Therapeutics Inc. (CCCC)
1.75
-0.09 (-4.89%)
At close: Mar 28, 2025, 3:59 PM
1.74
-0.33%
After-hours: Mar 28, 2025, 07:50 PM EDT
-4.89% (1D)
| Bid | 1.7 |
| Market Cap | 124.23M |
| Revenue (ttm) | 35.78M |
| Net Income (ttm) | -105.89M |
| EPS (ttm) | -1.52 |
| PE Ratio (ttm) | -1.15 |
| Forward PE | -3.24 |
| Analyst | Buy |
| Ask | 1.75 |
| Volume | 439,040 |
| Avg. Volume (20D) | 1,552,735 |
| Open | 1.83 |
| Previous Close | 1.84 |
| Day's Range | 1.74 - 1.82 |
| 52-Week Range | 1.74 - 8.29 |
| Beta | 3.00 |
About CCCC
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma an...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 2, 2020
Employees 110
Stock Exchange NASDAQ
Ticker Symbol CCCC
Website https://www.c4therapeutics.com
Analyst Forecast
According to 4 analyst ratings, the average rating for CCCC stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 642.86% from the latest price.
Stock Forecasts6 months ago
+13.79%
C4 Therapeutics shares are trading higher after th...
Unlock content with
Pro Subscription
